Royalty Pharma (RPRX) Competitors

Royalty Pharma (NASDAQ:RPRX) and Corcept Therapeutics (NASDAQ:CORT) are both finance companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Do institutionals and insiders hold more shares of RPRX or CORT?

54.3% of Royalty Pharma shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 18.9% of Royalty Pharma shares are held by insiders. Comparatively, 20.8% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Do analysts recommend RPRX or CORT?

Royalty Pharma currently has a consensus target price of $47.33, suggesting a potential upside of 40.96%. Corcept Therapeutics has a consensus target price of $138.25, suggesting a potential upside of 91.30%. Given Corcept Therapeutics' higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Corcept Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is RPRX or CORT more profitable?

Royalty Pharma has a net margin of 37.94% compared to Corcept Therapeutics' net margin of 22.35%. Corcept Therapeutics' return on equity of 24.54% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	37.94%	24.40%	14.01%
Corcept Therapeutics	22.35%	24.54%	20.24%

Does the media refer more to RPRX or CORT?

In the previous week, Corcept Therapeutics had 11 more articles in the media than Royalty Pharma. MarketBeat recorded 17 mentions for Corcept Therapeutics and 6 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.84 beat Corcept Therapeutics' score of 0.22 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has stronger earnings and valuation, RPRX or CORT?

Royalty Pharma has higher revenue and earnings than Corcept Therapeutics. Royalty Pharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.26B	8.34	$858.98M	$1.85	18.15
Corcept Therapeutics	$685.45M	11.18	$106.14M	$1.16	62.30

Does the MarketBeat Community believe in RPRX or CORT?

Corcept Therapeutics received 221 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 71.26% of users gave Corcept Therapeutics an outperform vote while only 67.98% of users gave Royalty Pharma an outperform vote.

Company	Underperform	Outperform
Royalty Pharma	Outperform Votes 327 67.98%	Underperform Votes 154 32.02%
Corcept Therapeutics	Outperform Votes 548 71.26%	Underperform Votes 221 28.74%

Which has more risk & volatility, RPRX or CORT?

Royalty Pharma has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500.

Summary

Corcept Therapeutics beats Royalty Pharma on 11 of the 19 factors compared between the two stocks.